To extend a drug patent, one drug company wants to give it to a Native American tribe
Share Now on:
It’s tough being a pharmaceutical company when your patent rights run out — the generic competition rushes in, and profits go down on a drug that you may have spent time and money to develop way back when.
But the drug company Allergan has been doing some creative thinking about this when it comes to an eye medicine called Restasis. They’re transferring the drug to a Native American tribe in upstate New York.
Veteran business columnist Joe Nocera, who wrote about the topic in Bloomberg View, stopped by to explain how this move works and what’ll happen to the availability of generic drugs if other companies start doing this. Below is an edited transcript.
David Brancaccio: So how are the good people of the St. Regis Mohawk tribe going to help Allergan?
Joe Nocera: Well, they are a sovereign entity. And if you’re a sovereign entity, you have certain immunities from federal law. And one of those immunities apparently is patents. Allegan has said we’re going to transfer our patent to you, you fine people of the Native American tribe the St. Regis Mohawks. We’re going to pay you an annual royalty and some upfront money, and our competitors who are trying to avoid our patent at the patent office will be stopped because the patent office can’t challenge a sovereign entity.
|Drug prices: how generics changed the game|
|Is competition the solution to high drug prices?|
Brancaccio: Now, in your column, you know that there are voices on Wall Street who seem to cheer this cool maneuver.
Nocera: Wall Street wants companies like Allergan to be able to maintain monopoly prices on brand name drugs. I mean, this is the really important part. Restasis has been on the market since 2002. Its original patent ran out in 2014. So there should have been generics on the market three years ago. But, companies now have learned that what you do is you make a little change in the dosage, you make a little change here, you make a little change in the formula. And you put a whole new bunch of patents around it, and you try to extend the patent life another 12 years or another 10 years. But, truly, it violates — at the minimum — the spirit of the law that basically says generics should be able to come in and give the American public cheaper prices. This is one reason, by the way, that health care costs so much.
Brancaccio: Now the pharma companies will say, “OK, you’re just looking at this one drug. In this case, Restasis. We spent tons of money trying to develop other drugs that failed. So this is one way we can recoup some of that.”
Nocera: The law is basically saying you’ve had your window, now it’s time to do something for the American people. And the companies are saying, well, we don’t really want to do anything for the American people — we really want to help our shareholders.
Brancaccio: Part of the trouble here is that there are several sets of laws. One, the Native nation and one, the laws of the United States.
Nocera: Well, that is true. And I should note that this maneuver — which is what it is — will be challenged. But if Allergan succeeds in doing this, I can guarantee you that the Native American tribes around the country are all going to get into the patent business, and every drug company on earth is going to start transferring patents to Native American tribes. So it really could put a damper on the generic business.
Marketplace is on a mission.
We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.
Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?